Natural Capsules Q1 FY24 consolidated PAT falls to Rs. 1.82 Cr

Natural Capsules Ltd. has reported total income of Rs. 37.87 crores during the period ended June 30, 2023

Granules India posts Q1 FY24 revenue from operations at Rs. 985.5 Cr

API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24

Lincoln Pharmaceuticals posts Q1 FY24 standalone net profit at Rs. 19.01 Cr

Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr

US FDA approval is in line with de-risking strategy for additional API site to service our global customer base

USFDA completes PAD E inspection of Marksans' Goa facility

The inspection was conducted at its Goa, Vema manufacturing facility

Granules India received USFDA approval for the ANDA filed for metoprolol succinate ER tablets

Briefs: Dr. Reddy's Laboratories and Aurobindo Pharma

The inspection closed with zero observations and a classification of No Action Indicated

Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr

The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023

Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP

The product is being launched in August 2023

Biocon Biologics announces leadership appointments